GovChime
Notice ID: 4ba05de659e943e68637a92f7c01b262Combined Synopsis/Solicitation

Vaccine Adverse Event Reporting System (VAERS) and Safety Monitoring Support for COVID-19 Vaccines

Archived on April 26, 2023. Original response deadline: . Full description on SAM.gov.

Overview

Response deadline
4:30 PM UTC−04:00
Posted
May 2, 2023
Notice type
Combined Synopsis/Solicitation
Set-aside
8(a) Set-Aside (FAR 19.8)
NAICS
541714: Research and Development in Biotechnology (except Nanobiotechnology)
Agency
Department of Health and Human ServicesFOOD AND DRUG ADMINISTRATION

Notice details

Office
FDA OFFICE OF ACQ GRANT SVCS
Last updated
Sep 9, 2025

Identifiers

Solicitation number
FDA-RFP-116785
Notice ID
4ba05de659e943e68637a92f7c01b262

Description

This project will fund a senior physician with Vaccine Adverse Event Reporting Subject Matter expertise to work on adverse neurological and other events associated with COVID-19 vaccinations. Currently there are two FDA-approved COVID-19 vaccines: Comirnaty (COVID-19 Vaccine, mRNA) Pikevax (COVID-19 Vaccine, mRNA) See attached solicitation for more information. There are four COVID-19 vaccines authorized for emergency use in the U.S.: Janssen (J&J) COVID-19 Vaccine Moderna COVID-19 Vaccine and Moderna COVID-19 Vaccine, Bivalent Novavax COVID-19 Vaccine, Adjuvanted Pfizer-BioNTech COVID-19 Vaccine and Pfizer-BioNTech COVID-19 Vaccine, Bivalent As with all vaccines and other medical products, although the vaccine development process and FDAs evaluation are rigorous and comprehensive, after a vaccine for COVID-19 is authorized under EUA by FDA, or following licensure (approval) of a BLA, additional pharmacovigilance will be conducted to monitor COVID-19 vaccine safety and effectiveness. Additionally, the senior physician will be tasked with various projects identified by OBPV/DPV to fulfill statutory obligations, user fee commitments, specific Center or Agency goals.

Full description on SAM.gov

Award Overview

No prior contract identified

No prior award matched this notice's agency, NAICS, place of performance and PSC within 18 months. It may be a new requirement.

Contacts

Documents

No documents available.

Lifecycle

Solicitation:FDA-RFP-116785
  1. Combined Synopsis
  1. 2×
    Combined SynopsisCurrentApr 18, 2023

    Vaccine Adverse Event Reporting System (VAERS) and Safety Monitoring Support for COVID-19 Vaccines

    Notice 4ba05de659e943e68637a92f7c01b262 on SAM.gov

Similar Opportunities

Title
Match
Phase
Deadline

Additional Details

Solicitation Number

FDA-RFP-116785

Archive Date

Apr 26, 2023

Office Address

Beltsville, MD, 20705